Helixgate

Helixgate

Uncategorized

Guarding biotech from China and big bets in longevity

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT’s Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar’s comments that the company is publishing  “not the right structures” in their research publications.

Listeners also will hear Allison’s interview with Joe Betts-LaCroix, CEO of the Sam Altman-backed longevity company Retro Biosciences. Retro is preparing for its first clinical data readout and examining just how much impact AI can have in drug development.

Read the rest…

Read More

Published

on

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT’s Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Neil Kumar’s comments that the company is publishing  “not the right structures” in their research publications.

Listeners also will hear Allison’s interview with Joe Betts-LaCroix, CEO of the Sam Altman-backed longevity company Retro Biosciences. Retro is preparing for its first clinical data readout and examining just how much impact AI can have in drug development.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Published

on

After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.​ ​Read More

Continue Reading

Uncategorized

Chile offers new data on food warning label efficacy

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Continue Reading

Uncategorized

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Published

on

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Continue Reading
Advertisement

Trending